NCT03398668已完成不适用
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline
研究概览
简要总结
This study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females Ages of 18 to 65 years old.
- •History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHD (International Classification of Headache Disorders)-III beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction).
- •Capable to corporate with the study protocol and to sign an informed consent.
排除标准
- •Patients having received Botox treatment in the head region in the prior 4 months.
- •Patients having received supraorbital or occipital nerve blocks in the prior 4 months.
- •History of Medication Overuse Headache.
- •Patients using opioid medication.
- •Allodynia: intolerance to supraorbital and/or occipital neurostimulation that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 10 minutes of neurostimulation).
- •Implanted metal or electrical devices in the head (not including dental implants).
- •Patient having had a previous experience with the Relievion™ device.
- •Patients who have concomitant epilepsy.
- •History of neurosurgical interventions.
- •Patients with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.
- •History of drug abuse or alcoholism.
- •Participation in current clinical study or participated in a clinical study within 3 months prior to this study.
- •Skin lesion or inflammation at the region of the stimulating electrodes.
- •Personality or somatoform disorder.
- •Pregnancy or Lactation.
- •Women with child bearing potential without medically acceptable method of contraception.
- •History of cerebrovascular event.
- •Subjects with recent brain or facial trauma (occurred less than 3 months prior to this study).
- •Patients using Cannabis
- •Patients with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters.
研究组 & 干预措施
Relievion device- Treatment stimulation
Active Comparator
Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
干预措施: Relievion device- Treatment stimulation (Device)
Sham Comparator: Relievion device- Sham Stimulation
Sham Comparator
Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
干预措施: Relievion Device- Sham stimulation (Device)
结局指标
主要结局
Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline
时间窗: 1 hour
visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable pain
次要结局
- Proportion of patients not having required rescue medication at 2 hours compared to baseline.(2 hours)
- Proportion of patients pain free at 1,2 and 24 hours from baseline (if rescue therapy was not used).(1, 2, 24 hours)
- Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).(24 hours)
- Proportion of "responders" ("responder" is defined as decrease of at least 50% in VAS pain score from baseline) at 1,2 and 24 hours from baseline (if rescue therapy was not used).(1, 2, 24 hours)
- Mean change of pain score (measured by VAS) at 2 hours compared to baseline (if rescue therapy was not used).(2 hours)
- Proportion of patients not having required rescue medication within 24 hours(24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of MigraineAcute MigraineNCT03631550Neurolief Ltd.187
已完成
不适用
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)MDDNCT04279522Neurolief Ltd.124
已完成
不适用
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related PainHeadache, MigraineNCT02438553Neurolief Ltd.40
进行中（未招募）
3 期
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis PigmentosaRetinitis PigmentosaNCT05926583Janssen Pharmaceutical K.K.4
已完成
不适用
Bilateral Oophorectomy Versus Ovarian ConservationOophorectomyHysterectomyNCT01007305University of California, San Francisco20